GLP-1 side effects tend to cluster around starting treatment and each dose increase, then ease as your body adjusts. Knowing that rhythm makes it easier to tell an expected adjustment from something that needs a call to your prescriber.
Why timing follows a pattern
Side effects are closely tied to titration, the step-by-step dose increases at the start of treatment. The best timing data come from a pooled analysis of the STEP 1–3 semaglutide trials, where the dose started at 0.25 mg weekly for 4 weeks and rose every 4 weeks to 2.4 mg at week 16. Gastrointestinal side effects were most common during or shortly after dose escalation, and 99.5% of them were non-serious (Wharton et al., Diabetes, Obesity and Metabolism, 2021, DOI (external link)). A review of 26 placebo-controlled trials likewise found side effects were mostly gastrointestinal: nausea, vomiting, diarrhea, and constipation (Moiz et al., Annals of Internal Medicine, 2025, DOI (external link)).
This is a general pattern, not a guarantee. Individual experience varies a lot, including between fast and slow responders, and the week ranges below are typical rather than exact.
Starting dose (first 2–4 weeks)
Nausea and early appetite changes often begin here. Some people have almost no symptoms at the starting dose; others find it the hardest adjustment period. Injection site reactions can also show up, and good technique and site rotation help.
Each dose increase (the days to couple of weeks after)
Expect a similar, sometimes stronger, wave of GI symptoms after each increase: nausea, possibly vomiting, and changes in bowel habits (constipation or diarrhea). In the STEP trials, individual bouts were short. The median episode lasted 8 days for nausea, 3 days for diarrhea, and 2 days for vomiting. The share of people with nausea, diarrhea, or vomiting peaked around week 20, just after the last increase, and fell after that. Fatigue is also reported more often on these drugs than on placebo (5–7% vs 3% in the Zepbound trials), and some people notice it most around dose increases. This is why the standard titration schedule raises the dose gradually: small steps keep each wave manageable.
Between increases, once adjusted
Symptoms usually ease between dose increases. Many people say they feel "normal" during these stretches, just with a much smaller appetite. Constipation is the exception. In the STEP trials the median constipation episode lasted 47 days (35 days on placebo), much longer than nausea, and a small share of people have GI symptoms throughout treatment.
Longer-term (months into treatment)
By now most people have settled into a stable pattern, often with few ongoing symptoms, at their maintenance dose. This is when longer-latency effects can appear. Hair loss from telogen effluvium generally starts about 2–3 months after a trigger such as rapid weight loss (Asghar et al., Cureus, 2020, DOI (external link)), and visible skin or facial changes (see our guide on GLP-1 face) track the amount of weight lost. Both are more likely to show up now than in the first few weeks.
Risks that don't follow a timeline
Gallbladder disease, pancreatitis, and mood changes (see our guide on mood changes and anhedonia) don't line up with titration steps and can appear at any point in treatment. Stay alert to them throughout, not just early on. If symptoms persist, get worse, or don't fit the pattern above, our guide on talking to your doctor about side effects that aren't improving can help you raise them.
Study findings above are attributed to their authors and were located via PubMed.
This article is for general education and is not medical advice. Talk with your prescriber or care team about your own situation.